Accessibility Menu
Fisher & Paykel Healthcare logo

Fisher & Paykel Healthcare(OTC) FSPKF

Current Price$22.96
Market Cap$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+247%
5 Year+18%
1 Year+6%
1 Month+3%
Fisher & Paykel Healthcare last closing stock price
MetricPriceDate
Last closeUSD 22.962026-07-21
Fisher & Paykel Healthcare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.26%USD 22.902026-07-13
1 month+3.3%USD 22.232026-06-15
3 month+1.05%USD 22.722026-04-16
Year to date+20.78%USD 19.012025-12-29
1 year+6.15%USD 21.632025-07-21
3 year+65.34%USD 13.892023-07-20
5 year+17.8%USD 19.492021-07-22
Since inception+247.31%USD 6.612003-07-31

Fisher & Paykel Healthcare Financials at a Glance

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

NZ$4.57B

Net Income (TTM)

NZ$999.87M

EPS (TTM)

$0.47

P/E Ratio

49.03

Dividend

$0.41

Beta (Volatility)

0.27 (Low)

Price

$22.96

Volume

3,800

Open

$22.96

Previous Close

$22.96

Daily Range

$22.96 - $22.96

52-Week Range

$18.98 - $25.65

Estimated Earnings Date

May 25, 2026

FSPKF News

senior woman relaxing in hammock reading book

2 Companies Whose Products, and Profits, Could Help You Sleep Better at Night

James HalleyApr 14, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and distribution of advanced medical devices and systems. The company focuses on respiratory care, surgical support, and sleep apnea management, serving both clinical and home environments.

Products and Services
  • Airvo 2 humidified high-flow nasal system
  • Optiflow nasal high-flow therapy solutions
  • Comprehensive range of hospital-grade respiratory products
Growth Outlook
  • Strong demand for respiratory products amid global health challenges
  • Expansion into emerging markets expected to drive revenue growth
  • Investment in R&D to enhance product offerings and innovation
Financial Highlights
  • Recent quarterly revenue of NZD 1.25 billion, reflecting robust performance
  • Net income of NZD 258 million, showcasing strong profitability
  • TTM gross profit margin of 64.16%, indicating operational efficiency
Fisher & Paykel Healthcare has established itself as a leader in the medical devices sector, particularly in respiratory care. The company's innovative products are essential in addressing acute and chronic health conditions, making it a critical player in the healthcare industry. Recent financial performance highlights a strong revenue trajectory, with significant net income reflecting effective cost management and operational efficiency. The company's commitment to research and development positions it well for future growth, particularly in emerging markets where demand for healthcare solutions is increasing. With a solid foundation and a focus on innovation, Fisher & Paykel Healthcare presents a compelling opportunity for potential investors interested in the healthcare sector.
AI Generated • Jul 21, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

7,661

CEO

Lewis George Gradon

Website

www.fphcare.com

Headquarters

Auckland, AU 2013, NZ

FSPKF Financials

Key Financial Metrics (TTM)

Gross Margin

64.16%

Operating Margin

28.52%

Net Income Margin

20.03%

Return on Equity

22.84%

Return on Capital

29.51%

Return on Assets

16.42%

Earnings Yield

2.04%

Dividend Yield

1.79%

Payout Ratio

53.85%

Stock Overview

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

587.30M

Volume

3.80K

Avg. Volume

2.14K

Financials (TTM)

Gross Profit

NZ$2.62B

Operating Income

NZ$515.56M

EBITDA

NZ$1.75B

Operating Cash Flow

NZ$1.45B

Capital Expenditure

-NZ$316.61M

Free Cash Flow

NZ$1.13B

Cash & ST Invst.

NZ$465.72M

Total Debt

NZ$146.10M

Fisher & Paykel Healthcare Performance Analysis

Fisher & Paykel Healthcare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31NZD 989,724,362-13.5%
20242024-03-31NZD 1,071,885,3748.3%
20252025-03-31NZD 1,201,103,59012.1%
20262026-03-31NZD 1,373,195,91814.3%
Fisher & Paykel Healthcare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-301.3%
Q42025-03-3134.6%
Q22025-09-30-14.7%
Q42026-03-3114.5%
Fisher & Paykel Healthcare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31NZD 0.27-40.8%
20242024-03-31NZD 0.14-48.6%
20252025-03-31NZD 0.38175.1%
20262026-03-31NZD 0.4722.7%
Fisher & Paykel Healthcare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30510.3%
Q42025-03-31146.2%
Q22025-09-30-43.8%
Q42026-03-3122.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

NZ$1.25B

+33.2%

Gross Profit

NZ$810.95M

+45.3%

Gross Margin

64.83%

N/A

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.93M

N/A

Employees

6,978

N/A

Net Income

NZ$258.06M

+920.0%

EBITDA

NZ$457.04M

+85.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

NZ$465.72M

+468.0%

Total Debt

NZ$146.10M

-22.7%

Accounts Receivable

NZ$346.24M

+34.6%

Inventory

NZ$330.58M

+3.2%

Long Term Debt

NZ$113.30M

+22.0%

Short Term Debt

NZ$32.80M

-65.9%

Return on Assets

16.42%

N/A

Return on Invested Capital

28.31%

N/A

Free Cash Flow

NZ$299.57M

+36.0%

Operating Cash Flow

NZ$421.58M

+54.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ERFSFEurofins Scientific SE
$73.75-0.36%
CHJTFCSPC Pharmaceutical Group Limited
$1.07+0.00%
ALBHFAlibaba Health Information Technology Limited
$0.43-5.29%
ALBBYAlibaba Health Information Technology Limited
$8.47+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TAT&T
$24.13+0.05%

Questions About FSPKF

What is the current price of Fisher & Paykel Healthcare?

Fisher & Paykel Healthcare is trading at $22.96 per share.

What is the 52-week range for Fisher & Paykel Healthcare?

Over the past 52 weeks, Fisher & Paykel Healthcare has traded between $18.98 and $25.65.

How much debt does Fisher & Paykel Healthcare have?

As of the most recent reporting period, Fisher & Paykel Healthcare reported total debt of NZ$83.34M.

How much cash does Fisher & Paykel Healthcare have on hand?

Fisher & Paykel Healthcare reported NZ$263.03M in cash and cash equivalents in its most recent financial results.

What is Fisher & Paykel Healthcare’s dividend yield?

Fisher & Paykel Healthcare currently has a dividend yield of 1.79%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services